▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Novus Therapeutics in the last 3 months. The average price target is $50.75, with a high forecast of $58.50 and a low forecast of $43.00. The average price target represents a ∞ upside from the last price of $0.00.
The current consensus among 2 investment analysts is to buy stock in Novus Therapeutics. This Buy consensus rating has held steady for over two years.
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.